ArticleOncology letters2011
Role of ERCC5 polymorphism in risk of hepatocellular carcinoma.
Article in Oncology letters, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- The association between XPG polymorphisms and cancer susceptibility: Evidence from observational studies.Medicine · 2017Pooled it
- Pooled it
- Article
- Effects of ERCC5 rs751402 Polymorphism on Oxidative Stress and the Impact of Curcumin on Catalase Activity in Breast Carcinogenesis.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Association ofWorld journal of gastroenterology · 2019Article
- Diagnostic and prognostic values of the mRNA expression of excision repair cross-complementation enzymes in hepatitis B virus-related hepatocellular carcinoma.Cancer management and research · 2018Article
- High expression of ERCC5 predicts a poor prognosis in hepatocellular carcinoma.International journal of clinical and experimental pathology · 2018Article
- Article
- Association of ERCC5 Genetic Polymorphisms With Cirrhosis and Liver Cancer.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Excision repair cross‑complementing rodent repair deficiency, complementation group 5 (ERCC5, XPG) is a key molecule in DNA damage repair. We analyzed the contribution of ERCC5 rs751402 polymorphism in increased susceptibility to hepatocellular carcinoma (HCC). A total of 96 patients diagnosed with HCC and 336 healthy controls provided blood samples for analysis of rs751402 genotypes. Demographic data and information on habitual use of tobacco and alcohol were collected. After adjusting for covariates, rs751402 homozygocity for allele C was found to confer a statistically significant protection [adjusted odds ratio (AOR)=0.56; 95% CI, 0.35‑0.89; p=0.01] against HCC, whereas rs751402 T alleles were associated with increased risk (AOR=1.69; 95% CI, 0.74‑3.87). Individuals with the inherited ERCC rs751402 CC genotype may experience significant protection against HCC, whereas individuals with T alleles appear to be exposed to higher risk.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.